MSH3: A Potential Drug Target and Biomarker (G4437)

Target Name: MSH3

NCBI ID: G4437

MSH3

MSH3: A Potential Drug Target and Biomarker

Mismatch repair (MMR) is a critical DNA repair pathway that helps maintain the genetic integrity of cells. Mutations in the MMR system have been implicated in various diseases, including cancer, neurodegenerative diseases, and systemic illnesses. One of the proteins involved in this pathway is MSH3, which is a potential drug target and biomarker for various diseases.

History of MSH3

MSH3, also known as Mismatch repair protein 1 (MRP1), was first identified in 2005 as a gene that encodes a protein involved in the MMR pathway. The protein encoded by MSH3 is composed of 158 amino acids and has a calculated molecular mass of 17 kDa. It is expressed in various tissues, including liver, spleen, and skeletal muscles, and is involved in theMMR pathway.

Disease-Related Functions of MSH3

MSH3 is involved in the MMR pathway, which is a critical pathway for repairing DNA mutations that occur during cell division.MMR is a complex process that involves multiple proteins, including MSH3, which work together to repair damaged DNA.

Mutations in the MMR pathway have been implicated in various diseases, including cancer, neurodegenerative diseases, and systemic illnesses. For example, studies have shown that individuals with certain genetic mutations, such as those in the MMR system, are at increased risk for developing cancer. Additionally, mutations in the MMR system have been linked to neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Potential Drug Target

The potential drug target for MSH3 is based on its involvement in the MMR pathway and its ability to repair damaged DNA. Drugs that target MSH3 have the potential to treat various diseases associated with MMR dysfunction, including cancer, neurodegenerative diseases, and systemic illnesses.

One approach to targeting MSH3 is to use small molecules that can inhibit its activity in the MMR pathway.such as inhibitors of DNA-protein interactions, which may disrupt the formation of the complex required for MSH3 to function.

Another approach is to use antibodies that recognize and target MSH3 directly. This approach has been used to treat various diseases, including cancer, and has the potential to treat MSH3-related diseases as well.

Biomarker

MSH3 can also serve as a biomarker for various diseases associated with MMR dysfunction. Studies have shown that individuals with certain genetic mutations, such as those in the MMR system, have lower levels of MSH3 in their tissues, which may be an indicator of the severity of their disease.

Conclusion

In conclusion, MSH3 is a protein involved in the MMR pathway that has been implicated in various diseases. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate its role in the development and treatment of these diseases. Further studies are needed to fully understand the MSH3-related complex processes and develop effective treatments.

Protein Name: MutS Homolog 3

Functions: Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS beta which binds to DNA mismatches thereby initiating DNA repair. When bound, the MutS beta heterodimer bends the DNA helix and shields approximately 20 base pairs. MutS beta recognizes large insertion-deletion loops (IDL) up to 13 nucleotides long. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis

The "MSH3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSH3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets